ClinicalTrials.gg

Program

conestat alfa

Also written as “Ruconest”, “Recombinant Human C1 Inhibitor” and “rhC1INH”.

Its studies are mostly in Angioedemas, Hereditary · COVID-19 · Fatigue Syndrome, Chronic, led by 2 companies.

Furthest: phase 4, since Sep 20, 20058 company-led studies, 1 open or runningNext primary completion: Jul 31, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pharming Group60 open or runningphase 3since Sep 20, 2005Sep 20, 2005none ahead
IMMUNOe Research Centers21 open or runningphase 4since Nov 6, 2026Jan 7, 2021Jul 31, 2027phase 4 · NCT07932002

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 20, 2005First study: phase 3 study in Angioedemas, HereditaryNew to Pharming GroupPharming Group · NCT00225147 · 77 enrolled · Netherlands
  2. Dec 1, 2005Phase 3 study in Angioedemas, HereditaryPharming Group · NCT00262301 · 75 enrolled · Netherlands, Romania
  3. Feb 25, 2009Phase 2 study in Genetic Diseases, InbornPharming Group · NCT00851409 · 25 enrolled · Netherlands, Romania
  4. May 19, 2011Phase 2 study in Angioedemas, HereditaryPharming Group · NCT01359969 · 57 enrolled · United States, Czechia, Germany and more
  5. Sep 16, 2014Phase 2 study in Angioedemas, HereditaryPharming Group · NCT02247739 · 32 enrolled · United States, Canada, Czechia and more
  6. Aug 26, 2020Phase 2 study in Confirmed Coronavirus DiseasePharming Group · NCT04530136 · 38 enrolled · United States
  7. Jan 7, 2021IMMUNOe Research Centers's first study: phase 2 study in Fatigue Syndrome, ChronicNew to IMMUNOe Research CentersIMMUNOe Research Centers · NCT04705831 · 40 enrolled · United States
  8. Nov 6, 2026Phase 4 study in COVID-19IMMUNOe Research Centers · NCT07932002 · 30 planned · United States

Ahead

  1. Jul 31, 2027Primary completion: phase 4 study in COVID-19IMMUNOe Research Centers · NCT07932002

TargetBeta

SERPING1 →read by rule
“A recombinant form of human complement component 1 esterase inhibitor (C1INH), a serine protease inhibitor normally present in human plasma, that can be used for the treatment of hereditary angioedema (HAE)”NCIt, by rule
“Plasma protease C1 inhibitor exogenous protein”ChEMBL 37, by rule

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07932002COVID-19 · United States4RecruitingIMMUNOe Research CentersJul 31, 202730
NCT04705831Fatigue Syndrome, Chronic · United States2CompletedIMMUNOe Research CentersMar 30, 202440
NCT04530136Confirmed Coronavirus Disease · United States2CompletedPharming GroupSep 7, 202138
NCT02247739Angioedemas, Hereditary · United States, Canada, Czechia and more2CompletedPharming GroupMay 201632
NCT01359969Angioedemas, Hereditary · United States, Czechia, Germany and more2CompletedPharming GroupJul 17, 201757
NCT00851409Genetic Diseases, Inborn · Netherlands, Romania2CompletedPharming GroupMar 201025
NCT00262301Angioedemas, Hereditary · Netherlands, Romania3CompletedPharming GroupJul 200975
NCT00225147Angioedemas, Hereditary · Netherlands3CompletedPharming GroupOct 200977

How it is read

Names in the registry

  • “Ruconest”, 3 entries
  • “Recombinant Human C1 Inhibitor”, 2 entries
  • “rhC1INH”, 1 entry
  • “Recombinant human C1 inhibitor”, 1 entry
  • “recombinant human C1 inhibitor”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.